Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.82 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.67 |
| ▸ | ADCY5 | O95622 | 4/20 | 0.64 |
| ▸ | PI4KA | P42356 | 1/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.61 |
| ▸ | AHCY | P23526 | 5/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19553487 | 0.95 | ADORA2A (0.91) | ADORA2AADORA1ADCY1ADORA2BADCY5 | |
| SCHEMBL8467390 | 0.94 | ADORA2A (0.88) | ADORA2AADORA1ADCY1ADORA2BADCY5 | |
| SCHEMBL29459142 | 0.90 | ADORA2A (1.00) | ADORA2AADORA1ADCY1ADORA2BADCY5 | |
| SCHEMBL984944 | 0.90 | ADORA2A (1.00) | ADORA2AADORA1ADCY1ADORA2BADCY5 | |
| Hydrochloric Acid SCHEMBL9193028 | 0.89 | ADORA2A (0.97) | ADORA2AADORA1ADCY1ADORA2BADCY5 | |
| SCHEMBL11222112 | 0.86 | ADORA2A (0.80) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL67131 | 0.85 | ADORA2A (0.74) | ADORA2AADORA1ADCY1ADORA2BADCY5 | |
| SCHEMBL1532103 | 0.85 | ADORA2A (0.74) | ADORA2AADORA1ADCY1ADORA2BADCY5 | |
| SCHEMBL26981114 | 0.85 | ADORA2A (0.74) | ADORA2AADORA1ADCY1ADORA2BADCY5 | |
| SCHEMBL2638945 | 0.85 | ADORA2A (0.74) | ADORA2AADORA1ADCY1ADORA2BADCY5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113214322-B | Green and environment-friendly preparation method of tenofovir | 山东立新制药有限公司 | 2022-10-25 | — | — | CN | claimed |
| CN-113214322-A | Green and environment-friendly preparation method of tenofovir | 山东立新制药有限公司 | 2021-08-06 | — | — | CN | claimed |
| CN-110655534-A | Tenofovir lipid monoester compound and preparation method and application thereof | 安徽贝克联合制药有限公司 | 2020-01-07 | — | — | CN | claimed |
| US-10155007-B2 | Synthesis method for improved tenofovir disoproxil fumarate using ion-exchange resin and method for preparing oral dissolving film form using the same | FIRSON (KR) | 2018-12-18 | — | — | US | claimed |
| CN-105985381-B | A kind of preparation method of tenofovir | 安徽贝克联合制药有限公司 | 2018-10-30 | — | — | CN | claimed |
| CN-107841771-A | It is a kind of based on the non-cyanide plating silvering solution composition of complexing ligands system and its application | 厦门大学 | 2018-03-27 | — | — | CN | claimed |
| CN-105646585-B | A kind of preparation method of (R) 9 [2 (phosphonium mesitoyl methoxy) propyl group] adenine | 扬州三友合成化工有限公司 | 2018-03-13 | — | — | CN | claimed |
| CN-107602613-A | A kind of preparation method of (R) 9 [2 (phosphonium mesitoyl methoxy) propyl group] adenine | 常州润联化工有限公司 | 2018-01-19 | — | — | CN | claimed |
| US-20170354668-A1 | Synthesis Method For Improved Tenofovir Disoproxil Fumarate Using Ion-Exchange Resin And Method For Preparing Oral Dissolving Film Form Using The Same | FIRSON (KR) | 2017-12-14 | — | — | US | claimed |
| CN-107021985-A | The synthetic method of pharmaceutical intermediate R 9 [2 (diethylphosphono methoxyl) propyl group] adenine | 四川理工学院 | 2017-08-08 | — | — | CN | claimed |
| CN-105985381-A | Preparation method for tenofovir | 安徽贝克联合制药有限公司 | 2016-10-05 | — | — | CN | claimed |
| CN-105646585-A | Preparation method of (R)-9-[2-(phosphoryl methoxyl)propyl]-adenine | 扬州三友合成化工有限公司 | 2016-06-08 | — | — | CN | claimed |
| EP-2462935-B1 | Process for the preparation of tenofovir | LAURUS LABS PRIVATE LTD (IN) | 2015-01-21 | — | — | EP | claimed |
| US-5733788-A | PURIFICATION, LIQUID CHROMATOGRAPHY | GILEAD SCIENCES, INC. (US) | 1998-03-31 | — | — | US | claimed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| CN-113214322-B | Green and environment-friendly preparation method of tenofovir | 山东立新制药有限公司 | 2022-10-25 | — | — | CN | disclosed |
| WO-1996006159-A1 | UNIQUE ASSOCIATED KAPOSI'S SARCOMA VIRUS SEQUENCES AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1996-02-29 | — | — | WO | disclosed |
| WO-1995012313-A1 | VIRUS ASSOCIATED MULTIPLE SCLEROSIS: TREATMENTS, PREVENTION AND DIAGNOSIS THEREOF | PATHOGENESIS CORPORATION (US) | 1995-05-11 | — | — | WO | disclosed |
| US-4230708-A | SYNERGISTIC | STICHTING REGA V.Z.W. (BE) | 1980-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170354668-A1 | Synthesis Method For Improved Tenofovir Disoproxil Fumarate Using Ion-Exchange Resin And Method For Preparing Oral Dissolving Film Form Using The Same | DHX36, DHX30, SAMHD1 | ADORA2A 3320/4885ADORA1 1603/4885ADCY1 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.